TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00847379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ataluren
Description: Ataluren oral powder for suspension will be administered as per dose and schedule specified in the arm.
Study: NCT02672865

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
Description: Hyperthermic intraperitoneal chemotherapy (HIPEC) is a procedure in which the internal parts of the abdomen are bathed in a warm solution of anti-cancer medications for 90 minutes.
Study: NCT04224441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorpromazine Pill
Description: The experimental treatment involves the combination of chlorpromazine to the standard treatment with temozolomide solely in the adjuvant phase (after radio-chemotherapy, temozolomide for 5 days every 28, at a dose of 150-200 mg/mq for 6 cycles) of the Stupp protocol. Chlorpromazine will be administered at a dose of 50 mg/day concomitantly with the adjuvant treatment with temozolomide
Study: NCT02794896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose propofol, fentanyl and sevoflurane
Description: Deep Anesthesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose propofol, fentanyl and sevoflurane
Description: Shallow Anesthesia
Study: NCT00513084

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SDT and Motivational Interviewing in Obesity Treatment
Description: Thirty group sessions, designed to follow SDT, covering PA, eating/nutrition, body image, and other cognitive-behavioral contents. Central to the intervention are improving autonomy, intrinsic motivation, and self-regulation of behavior change. Accepting ambivalence for change, rolling with resistance, and developing discrepancy were used throughout the program, with an emphasis on promoting intrinsic, self-regulated motivation for exercise and weight control.
Study: NCT03954886

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Plus powered optical lens
Description: A plus powered optical lens will be placed in front of one eye.
Study: NCT06040684

Intervention type: DIAGNOSTIC_TEST
Intervention: Level of antibodies
Description: The level of antibodies against transplanted kidney in patients with a severe acute infection will be measured upon admission and then in 5 weeks.
Study: NCT03205358

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine
Description: 0.5 milliliter (mL), Intramuscular (IM)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningococcal Polysaccharide groups A, C, W-135 and Y Conjugate Vaccine
Description: 0.5 mL, IM
Study: NCT00047008

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Accelerated fractionation radiation therapy
Description: Radiation to the initial target volume encompassing the gross and subclinical disease sites will be delivered in 1.8 Gy per fraction, five fractions a week to 54 Gy in 30 fractions over 6 weeks. At 32.4 Gy/18 Fx (i.e., latter part of week 4), the boost volume covering gross tumor and clinically/radiologically involved nodes will receive boost irradiation of 1.5 Gy/Fx as second daily fraction (at least 6 h interval) for a total of 12 treatment days (18 Gy total). The primary tumor and clinically/radiologically involved nodes will receive 72 Gy in 42 fractions over 6 weeks and uninvolved nodes will receive 54 Gy in 6 weeks. Clinically/radiologically negative posterior neck should receive a minimum dose of 50.4 Gy at 3 cm. The anterior lower neck field will be treated with 1.8 Gy per fraction at 3-cm depth to a total dose of 50.4 Gy in 28 fractions in 5.6 weeks.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional surgery for select patients
Description: Surgical removal (salvage resection) of the primary tumor should be performed if biopsy-proven cancer remains more than three months after completion of therapy. The nature of the surgical resection should be dictated by the extent of tumor at the initial evaluation. The operation should be conducted using accepted criteria for primary surgical treatment of the cancer.~A planned neck dissection for patients with multiple neck nodes or with lymph nodes exceeding 3 cm in diameter (N2a, N2b, N3) is mandatory, regardless of the clinical and/or radiographic response. A neck dissection is required for patients with N1 disease if a palpable or worrisome radiographic abnormality persists in the neck six weeks after completion of therapy. Surgery should be performed within 2 weeks once the decision for neck dissection is made.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Conventional surgery for select patients
Description: Surgical removal (salvage resection) of the primary tumor should be performed if biopsy-proven cancer remains more than three months after completion of therapy. The nature of the surgical resection should be dictated by the extent of tumor at the initial evaluation. The operation should be conducted using accepted criteria for primary surgical treatment of the cancer.~A planned neck dissection for patients with multiple neck nodes or with lymph nodes exceeding 3 cm in diameter (N2a, N2b, N3) is mandatory, regardless of the clinical and/or radiographic response. A neck dissection is required for patients with N1 disease if a palpable or worrisome radiographic abnormality persists in the neck six weeks after completion of therapy. Surgery should be performed within 2 weeks once the decision for neck dissection is made.
Study: NCT02884271

Intervention type: PROCEDURE
Intervention: cardiopulmonary resuscitation
Description: start cardiopulmonary resuscitation
Study: NCT01660230

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 3K3A-APC, diluted in 0.9% sodium chloride in water

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 3K3A-APC, diluted in 0.9% sodium chloride in water

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 3K3A-APC, diluted in 0.9% sodium chloride in water

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 3K3A-APC, diluted in 0.9% sodium chloride in water

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 3K3A-APC, diluted in 0.9% sodium chloride in water

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 3K3A-APC, diluted in 0.9% sodium chloride in water
Study: NCT01607463

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (Empi, USA)
Description: In the active TENS group, TENS at 80 pulsed currents per second (PPS) with a pulse duration of 200 μs were delivered for 20 minutes. Current amplitude was slowly increased until a level was reached that participants reported was the maximum level they could tolerate below pain threshold without noticeable muscle contraction and maintained this intensity.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Transcutaneous electrical nerve stimulation (Empi, USA)
Description: In the placebo group the TENS device had no current output although the power on indicator light remained active.
Study: NCT03715140

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crucumin
Description: Evaluation of the effect of Crucumin in patients with osteoarthritis

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02078024

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVM plus ALB

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVM plus ALB

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVM plus ALB

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IVM

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVM
Study: NCT00637624

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-Acetylcysteine
Description: N-Acetylcysteine intravenously once every 3 weeks 40 mg/kg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once every 3 weeks intravenous saline fluid
Study: NCT00956722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bovine Colostrum Powder
Description: Bovine Colostrum Powder (Biogard)
Study: NCT00562822

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arthroscopic surgery
Description: Arthroscopic surgery to treat unresolved symptoms of osteoarthritis of the knee

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical and medical therapy
Description: Treatment with physical and medical therapy alone

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical and medical therapy
Description: Treatment with physical and medical therapy alone
Study: NCT03910790

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 19 gauge needle liver biopsy
Description: Obtaining liver tissue with a 19 gauge core needle and whether a good core biopsy can be obtained without the use of suction and secondly to determine the diagnostic yield and safety of 19 gauge core needle for liver biopsy.
Study: NCT04414813

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Amniotic Epithelial Stem Cells
Description: Stereotactic transplantation of hAESCs for participants with PD.
Study: NCT03167190

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Point-of-care ultrasound
Description: A point-of-care ultrasound machine will be utilized to identify and mark midline and the interspinous space based on visualization of spinous processes.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Traditional Landmark-based Lumbar Puncture
Description: Palpation of anatomical landmarks to identify midline and interspinous space
Study: NCT01695590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRLX 93936
Description: PRLX 93936 administered IV 3 days a week (Monday, Wednesday and Friday) for 3 weeks followed by a 9 day rest period = 1 cycle, multiple cycles may be administered
Study: NCT05094583

Intervention type: BEHAVIORAL
Intervention: Use of SmokeFree app
Description: Intervention Arm
Study: NCT03391037

Intervention type: DIAGNOSTIC_TEST
Intervention: Internal Jugular Vein Distensibility
Description: . 40 donor candidates for right lobe hepatectomy for living donor liver transplantation were enrolled. During period of hypovolemia (T0) left IJV scanned and measured. After a given fluid bolus in the form of ringer acetate 5 ml / Kg. ultrasonic and hemodynamic measurements were reassessed 10 minutes (T 10) after the fluid resuscitation
Study: NCT02969369

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEP-363856
Description: SEP-363856 (25, 50, or 75mg/day)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsule
Description: Placebo once daily
Study: NCT03885258

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin Replacement Therapy
Description: Melatonin (Aché Pharmaceutics, Brazil), 3 mg, administered in the evening, 30 minutes before the usual bedtime, every day for 3 months. After discontinuation of melatonin therapy, patients are followed up for 6 months to assess safety parameters and cardiac autonomic activity.
Study: NCT03981770

Intervention type: DRUG
Intervention: General anesthesia
Description: For maintenance of propofol anesthesia, total intravenous anesthesia was administered by using propofol (Fresenius Kabi, Austria GmbH) at a plasma target concentration (Marsh pharmacokinetic model software) of 2.5-4 μg/ml. Remifentanil (0.2-0.5 μg/kg/min) was given to all patients during the operation.

Intervention type: DRUG
Intervention: General anesthesia
Description: For maintenance of propofol anesthesia, total intravenous anesthesia was administered by using propofol (Fresenius Kabi, Austria GmbH) at a plasma target concentration (Marsh pharmacokinetic model software) of 2.5-4 μg/ml. Remifentanil (0.2-0.5 μg/kg/min) was given to all patients during the operation.
Study: NCT03385460

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ESWL BOTOX
Description: ESWL after intrravesical BOTOX
Study: NCT01322269

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HQK-1001
Description: HQK-1001 tablets, once daily for daily 26 weeks
Study: NCT01571804

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pregabalin
Description: one capsule of pregabalin 150 mg and one placebo capsule 1 hr before surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pregabalin
Description: two capsules of pregabalin 150 mg 1 hr before surgery
Study: NCT02638337

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ospemifene
Description: 60 mg tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet identical to the ospemifene tablet without drug
Study: NCT03578198

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab + MG4101
Description: 1. Induction phase:~   * Rituximab (Truxima) 375mg/m2 IV Weekly (X4)~  * MG4101 3x107 cells/kg IV Weekly (X4)~2. Maintenance phase~   * Rituximab (Truxima) 375mg/m2 IV q 4 weeks (X4)~  * MG4101 3x107 cells/kg IV q 4 weeks (X4)
Study: NCT03710798

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low carbohydrate high fat diet
Description: Energy balanced low carbohydrate high fat diet during 6 weeks. Then 6-week reintroduction of a healthy normal diet
Study: NCT02192242

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acute ischemic pain
Description: acute ischemic pain was induced by treadmill exercise
Study: NCT03428698

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Aminogam
Description: A lower third molar was extracted. All the surgical tools and materials as well as the surgical field were sterile. A full-thickness flap was raised and, if necessary, osteotomy and tooth sectioning were performed using a straight handpiece with dedicated burs under copious irrigation with sterile saline solution. The extraction was completed with curved and straight extractors, the socket was closely inspected and the dental follicle was removed. Depending on the group to which the patient was assigned, one of the following procedures was carried out.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aminogam
Description: A lower third molar was extracted. All the surgical tools and materials as well as the surgical field were sterile. A full-thickness flap was raised and, if necessary, osteotomy and tooth sectioning were performed using a straight handpiece with dedicated burs under copious irrigation with sterile saline solution. The extraction was completed with curved and straight extractors, the socket was closely inspected and the dental follicle was removed. Depending on the group to which the patient was assigned, one of the following procedures was carried out.
Study: NCT03248505

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conventional TENS
Description: Transcutaneous Electrical Nerve Stimulation (frequency of 100 Hz, pulse duration of 100 micro-seconds and sensory-level amplitude) with two electrodes in each side of the lumbar spinal.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Burst TENS
Description: Burst-modulated TENS with carrier frequency of 100 Hz, burst-modulated at 4Hz, pulse duration of 200 micro-seconds and motor-level amplitude.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Description: 1,5 Kg of crushed ice pack on lumbar spine.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Burst TENS + Cryotherapy
Description: Burst-modulated TENS with carrier frequency of 100 Hz, burst-modulated at 4Hz, pulse duration of 200 micro-seconds and motor-level amplitude plus 1,5 Kg of crushed ice pack on lumbar spine.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conventional TENS + Cryotherapy
Description: Transcutaneous Electrical Nerve Stimulation (frequency of 100 Hz, pulse duration of 100 micro-seconds and sensory-level amplitude) plus s 1,5 Kg of crushed ice pack on lumbar spine.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo TENS
Description: TENS device turned on, but with zero amplitude.
Study: NCT01343459

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: HIOB
Description: IOERT single shot as a boost followed by hypofractionated WBRT (HIOB)~* IOERT is performed on mobile or fixed linacs~* Reference dose: 11 Gy specified as maximum dose, with a minimum target volume dose of 90% encompassing the PTV (i.e. 10 Gy).~WBRT~* must start within day 36- 56 postoperatively (week 6 - 8 p.o.) in case of adjuvant hormonal treatment (or no further tumor specific medication)~* In case of adjuvant chemotherapy, a time - gap between IOERT and WBRT up to 9 months is allowed.~* Single reference dose per fraction: 2,7 Gy (ICRU)~* Number of fractions: 15, Number of fractions per week: 5~* Total WBRT dose: 40,5 Gy
Study: NCT03951805

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin icodec
Description: Administered subcutaneously SC once weekly. Starting dose will be 70U.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin icodec
Description: Administered subcutaneously SC once weekly. Starting dose will be 70U.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin icodec
Description: Administered subcutaneously SC once weekly. Starting dose will be 70U.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine
Description: Administered subcutaneously SC once daily.The starting dose will be 10U.
Study: NCT01154387

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti-Thymocyte Globulin
Description: 1.5mg/kg IV on Day of Transplant and 1.0-1.5 mg/kg IV once daily for a minimum of 4.5mg/kg and a maximum of 7.5mg/kg total cumulative dose
Study: NCT01660230

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 3K3A-APC, diluted in 0.9% sodium chloride in water

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 3K3A-APC, diluted in 0.9% sodium chloride in water

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 3K3A-APC, diluted in 0.9% sodium chloride in water

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 3K3A-APC, diluted in 0.9% sodium chloride in water

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% NaCl in water
Study: NCT00742131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1363089
Description: GSK1363089 will be administered orally as a cinnamon-flavored liquid (250 milligrams of GSK1363089 in 50 milliliters liquid \[5 milligrams/milliliter\] or 1000 milligrams of GSK1363089 in 50 milliliters liquid \[20 milligrams/milliliter\]) or as solid capsules of 20, 100, and/or 200 milligrams.
Study: NCT00472654

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Weight Loss
Description: Diet for weight loss for 6 weeks; all weight loss participants will attend 6 weekly counseling sessions (about 50 minutes per session)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight Loss
Description: Diet for weight loss for 6 weeks; all weight loss participants will attend 6 weekly counseling sessions (about 50 minutes per session)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D 2500 IU
Description: Daily Vitamin D 2500 IU supplement for 6 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D 2500 IU
Description: Daily Vitamin D 2500 IU supplement for 6 weeks

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Weight Maintenance
Description: Diet for weight maintenance for 6 weeks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weight Maintenance
Description: Diet for weight maintenance for 6 weeks
Study: NCT00586716

Intervention type: DRUG
Group type: OTHER
Intervention: intravenous immune globulin
Description: 0.5-2 gm/kg monthly (maximum dose of 140 gm/dose) x 4 treatments

Intervention type: DRUG
Group type: OTHER
Intervention: intravenous immune globulin
Description: 0.5-2 gm/kg monthly (maximum dose of 140 gm/dose) x 4 treatments
Study: NCT01268540

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FY-60AD
Description: Phacoemulsification cataract extraction followed by implantation of an aspheric non-toric intraocular lens: Model FY-60AD.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NHT15, NHT30, & NHT53
Description: Phacoemulsification cataract extraction followed by implantation of an aspheric toric intraocular lens: Model NHT15, NHT30, or NHT53.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NHT15, NHT30, & NHT53
Description: Phacoemulsification cataract extraction followed by implantation of an aspheric toric intraocular lens: Model NHT15, NHT30, or NHT53.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NHT15, NHT30, & NHT53
Description: Phacoemulsification cataract extraction followed by implantation of an aspheric toric intraocular lens: Model NHT15, NHT30, or NHT53.
Study: NCT02243371

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CRS-207
Description: 1 × 10\^9 CFU administered IV on Day 2 of Cycles 3-6

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CRS-207
Description: 1 × 10\^9 CFU administered IV on Day 1 of Cycles 3-6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: 3 mg/kg administered IV on Day 1 of Cycles 1-6

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GVAX
Description: 5x10\^8 cells administered in 6 intradermal injections on Day 2 of Cycles 1 and 2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GVAX
Description: 5x10\^8 cells administered in 6 intradermal injections on Day 2 of Cycles 1 and 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CY
Description: 200 mg/m\^2 administered IV on Day 1 of Cycles 1 and 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CY
Description: 200 mg/m\^2 administered IV on Day 1 of Cycles 1 and 2
Study: NCT01995500

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BioNIR
Description: drug-eluting stent

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Resolute
Description: drug-eluting stent